Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ASLAN001 + oxaliplatin + capecitabine
- Development stage
- Unknown
- Lead developer
- ASLAN Pharmaceuticals
- Modality
- Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
ASLAN001 (varlitinib) combined with oxaliplatin and capecitabine is an investigational multi-drug regimen studied for the treatment of advanced or metastatic solid tumors, particularly those with dysregulated EGFR or HER2 signaling. Varlitinib is a potent, reversible small-molecule inhibitor targeting the HER-family of receptor tyrosine kinases—specifically EGFR (HER1), HER2, and HER4. By inhibiting these receptors, varlitinib aims to block key pathways involved in tumor growth and survival. Oxaliplatin is a platinum-based chemotherapeutic agent that induces DNA crosslinking and apoptosis in cancer cells. Capecitabine is an oral prodrug converted to 5-fluorouracil (5-FU) in vivo, which inhibits thymidylate synthase and disrupts DNA synthesis. This combination has been evaluated in early-phase clinical trials for patients with metastatic solid tumors suitable for CAPOX regimens or mFOLFOX6[5][4].
- Other names
- varlitinib + oxaliplatin + capecitabine
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)TS (Thymidylate synthase)ERBB4 (Erb-b2 receptor tyrosine kinase 4)EGFR T790M (Epidermal growth factor receptor T790M mutant)DNAABCG2 (Breast cancer resistance protein)
Beyond the preview
Go deeper on ASLAN001 + oxaliplatin + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ASLAN001 + oxaliplatin + capecitabine.